iShares MSCI Indonesia ETF vs Medtronic PLC — how do they compare? iShares MSCI Indonesia ETF trades at $11.8 (market cap $409.22M), while Medtronic PLC trades at $87.75 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 274.3× iShares MSCI Indonesia ETF's market cap, and Medtronic PLC pays a 3.28% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 75 Days and Medtronic PLC for 63 Days on average.
| EIDO | MDT | |
|---|---|---|
Market Cap | $409.22M | $112.24B |
Volume | 879,527 | 105,663,236 |
52-Week High | $19.22 | $105.35 |
52-Week Low | $10.80 | $73.75 |
Typical Hold Time | 75 Days | 63 Days |
Sector | — | Health |
Enterprise Value | — | $131.58B |
Dividend Yield | — | 3.28% |
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.86, down 0.59% with bearish technical signals from moving averages. The ETF faces headwinds as foreign capital rotates away from Asian markets, with recent news highlighting Indonesia's failure to benefit from commodity gains despite attractive valuations. Trading volume declined 21% below average, indicating reduced investor interest.
The outlook remains cautious with technical weakness outweighing valuation appeal. Key risks include heavy financial sector exposure (44%) and limited EPS growth potential. Seasonal patterns historically favor July-August performance, but current market dynamics suggest continued pressure on Indonesian equities amid regional capital outflows.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →